glp 1 microdosing menopause GLP-1s: A Doctor's Guide to Gentle, Effective Metabolic Reset: Shamsah Amersi, MD: OB-GYNs Dr. Peter A. Khamvongsa |

I find it interesting how few continue beyond 1+ year, and wonder what sort of yo-yo experience that could mean in the future years of benefit programs

Eli Lilly has not publicly announced pediatric clinical trials for orforglipron as of early 2026, but the commercial and clinical logic for eventual pediatric development is strong

Market Intelligence: The GLP-1 Shift The Trend: 47% rise in hair loss inquiries Primary Cause: Telogen Effluvium (Shedding) Metabolic Risk: Muscle Sarcopenia Skin Profile: Accelerated Laxity The Fix: The Piazza "Triple Threat" Protocol Target: Scalp, Skin, and Muscle Clinical Insight: Rapid weight loss triggers a survival response

doi: 10.1007/s00125-010-2028-x 168 LiljedahlLPedersenMHMcGuireJNJamesP